
### [NCIT:C27911](http://purl.obolibrary.org/obo/NCIT_C27911)
**Label:** Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

**Subclasses:** [NCIT:C7847](http://purl.obolibrary.org/obo/NCIT_C7847) (Stage 0 Chronic Lymphocytic Leukemia), [NCIT:C7304](http://purl.obolibrary.org/obo/NCIT_C7304) (Splenic Small Lymphocytic Lymphoma), [NCIT:C7886](http://purl.obolibrary.org/obo/NCIT_C7886) (Refractory Chronic Lymphocytic Leukemia), [NCIT:C45264](http://purl.obolibrary.org/obo/NCIT_C45264) (Cutaneous Chronic Lymphocytic Leukemia), [NCIT:C8115](http://purl.obolibrary.org/obo/NCIT_C8115) (Stage II Small Lymphocytic Lymphoma), [NCIT:C7300](http://purl.obolibrary.org/obo/NCIT_C7300) (Splenic Manifestation of Chronic Lymphocytic Leukemia), [NCIT:C7540](http://purl.obolibrary.org/obo/NCIT_C7540) (Small Lymphocytic Lymphoma), [NCIT:C8154](http://purl.obolibrary.org/obo/NCIT_C8154) (Recurrent Small Lymphocytic Lymphoma), [NCIT:C3163](http://purl.obolibrary.org/obo/NCIT_C3163) (Chronic Lymphocytic Leukemia), [NCIT:C8141](http://purl.obolibrary.org/obo/NCIT_C8141) (Stage IV Small Lymphocytic Lymphoma), [NCIT:C7876](http://purl.obolibrary.org/obo/NCIT_C7876) (Stage III Chronic Lymphocytic Leukemia), [NCIT:C8846](http://purl.obolibrary.org/obo/NCIT_C8846) (Refractory Small Lymphocytic Lymphoma), [NCIT:C7875](http://purl.obolibrary.org/obo/NCIT_C7875) (Stage II Chronic Lymphocytic Leukemia), [NCIT:C8645](http://purl.obolibrary.org/obo/NCIT_C8645) (Recurrent Chronic Lymphocytic Leukemia), [NCIT:C8128](http://purl.obolibrary.org/obo/NCIT_C8128) (Stage III Small Lymphocytic Lymphoma), [NCIT:C131873](http://purl.obolibrary.org/obo/NCIT_C131873) (Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma), [NCIT:C8646](http://purl.obolibrary.org/obo/NCIT_C8646) (Stage IV Chronic Lymphocytic Leukemia), [NCIT:C7874](http://purl.obolibrary.org/obo/NCIT_C7874) (Stage I Chronic Lymphocytic Leukemia), [NCIT:C7176](http://purl.obolibrary.org/obo/NCIT_C7176) (Aleukemic Chronic Lymphocytic Leukemia), [NCIT:C36273](http://purl.obolibrary.org/obo/NCIT_C36273) (Small Lymphocytic Lymphoma with Plasmacytoid Differentiation), [NCIT:C37201](http://purl.obolibrary.org/obo/NCIT_C37201) (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with Immunoglobulin Heavy Chain Variable-Region Gene Somatic Hypermutation), [NCIT:C36272](http://purl.obolibrary.org/obo/NCIT_C36272) (Chronic Lymphocytic Leukemia with Plasmacytoid Differentiation), [NCIT:C37202](http://purl.obolibrary.org/obo/NCIT_C37202) (Chronic Lymphocytic Leukemia with Immunoglobulin Heavy Chain Variable-Region Gene Somatic Hypermutation), [NCIT:C8070](http://purl.obolibrary.org/obo/NCIT_C8070) (Stage I Small Lymphocytic Lymphoma), [NCIT:C37203](http://purl.obolibrary.org/obo/NCIT_C37203) (Small Lymphocytic Lymphoma with Immunoglobulin Heavy Chain Variable-Region Gene Somatic Hypermutation), [NCIT:C37204](http://purl.obolibrary.org/obo/NCIT_C37204) (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene), [NCIT:C37205](http://purl.obolibrary.org/obo/NCIT_C37205) (Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene), [NCIT:C37206](http://purl.obolibrary.org/obo/NCIT_C37206) (Small Lymphocytic Lymphoma with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene), 

**Class expressions from DL-Learner:**

- Thing 53.49%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39961](http://purl.obolibrary.org/obo/NCIT_C39961) (Penile Basal Cell Carcinoma))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39959](http://purl.obolibrary.org/obo/NCIT_C39959) (Mixed Squamous Cell Carcinoma of the Penis))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39957](http://purl.obolibrary.org/obo/NCIT_C39957) (Epididymal Adenocarcinoma))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39956](http://purl.obolibrary.org/obo/NCIT_C39956) (Rete Testis Adenoma))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 37.99%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 37.99%


